BPH1222

BPH1222 is a **lipophilic bisphosphonate**, structurally related to zoledronic acid, developed as an anti-cancer agent. Unlike traditional hydrophilic bisphosphonates, BPH1222's increased lipophilicity allows for improved cell permeability and antitumor efficacy, particularly in tumors resistant to existing therapies. Its principal mechanism involves the **inhibition of farnesyl diphosphate synthase** and **geranylgeranyl diphosphate synthase**, resulting in disruption of prenylation of small G-proteins such as KRAS and Rheb. This impairs signaling pathways, especially the PI3K/Akt and mTOR pathways, leading to inhibition of tumor growth and induction of apoptosis. BPH1222 has demonstrated superior efficacy to zoledronic acid in preclinical models of malignant melanoma, lung adenocarcinoma (interest in **KRAS-mutant** tumors), and colorectal cancer, both in vitro and in vivo. Combination with mTOR inhibitors (e.g., rapamycin) further enhances tumor suppression by promoting autophagic cell death and inhibiting compensatory NF-κB activation[1][3][5][7][9].